8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 15, 2024)

Filed February 15, 2024For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on February 15, 2024, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2023. The key takeaway for investors is the release of this financial data, which is contained within an attached press release (Exhibit 99.1). This filing serves as the official notification of their latest performance metrics, including revenue, profitability, and potentially forward-looking statements or guidance, though the specifics of these results are detailed in the furnished press release rather than the 8-K itself. Investors should carefully review the accompanying press release for comprehensive details on Alnylam's financial condition and operational results for the period. This includes understanding the company's revenue generation, cost management, and any significant developments impacting their financial outlook. The 8-K filing itself acts as a regulatory gateway to this crucial financial information, highlighting the company's commitment to timely disclosure of material updates.

Key Highlights

  • 1Alnylam Pharmaceuticals announced its Q4 and full-year 2023 financial results on February 15, 2024.
  • 2The financial results are detailed in a press release furnished as Exhibit 99.1 to the Form 8-K.
  • 3This filing serves as the official notification of the company's financial performance for the reported periods.
  • 4Investors are directed to the press release for specific financial data and operational updates.
  • 5The 8-K itself does not contain the detailed financial statements but references the external press release.
  • 6Information furnished under Item 2.02 is not deemed 'filed' for specific regulatory purposes unless incorporated by reference.

Frequently Asked Questions

The detailed financial results are located in the press release furnished as Exhibit 99.1 to the Form 8-K filed by Alnylam Pharmaceuticals on February 15, 2024. You should refer to this exhibit for specific revenue, earnings, and other financial performance data.

This 8-K filing is significant because it formally announces Alnylam's latest financial results, providing investors with updated information on the company's performance. It signals that key financial metrics and potentially strategic updates are now publicly available through the associated press release.

No, the 8-K filing itself, specifically Item 2.02, states that the information is furnished via an attached press release (Exhibit 99.1). The detailed financial statements and performance metrics are within that press release, not directly in the 8-K document itself.

When information is 'furnished' under Item 2.02 of an 8-K, it means the company is providing the information to the SEC but it is not subject to the same liability provisions under Section 18 of the Exchange Act as 'filed' information. However, it is still considered important disclosure for investors and is often incorporated by reference into other SEC filings.